BRPI0413908A - formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo - Google Patents

formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo

Info

Publication number
BRPI0413908A
BRPI0413908A BRPI0413908-9A BRPI0413908A BRPI0413908A BR PI0413908 A BRPI0413908 A BR PI0413908A BR PI0413908 A BRPI0413908 A BR PI0413908A BR PI0413908 A BRPI0413908 A BR PI0413908A
Authority
BR
Brazil
Prior art keywords
disorder
pharmaceutical formulation
neurotherapeutic
oral dosage
compound
Prior art date
Application number
BRPI0413908-9A
Other languages
English (en)
Inventor
Gary A Koppel
Michael O Chaney
Original Assignee
Revaax Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revaax Pharmaceuticals Llc filed Critical Revaax Pharmaceuticals Llc
Publication of BRPI0413908A publication Critical patent/BRPI0413908A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36—Methylene radicals, substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/60—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 3 and 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA NEUROTERAPêUTICA EM FORMA DE DOSAGEM ORAL, COMPOSTO, E, MéTODO DE TRATAMENTO DE UM DISTúRBIO COMPORTAMENTAL OU UM DISTúRBIO COGNITIVO". Descreve-se o tratamento de distúrbios neurológicos usando composições de cefazolina e composições farmacêuticas incluindo formas de dosagem oral que incluem composições de cefazolina.
BRPI0413908-9A 2003-08-25 2004-08-24 formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo BRPI0413908A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49758803P 2003-08-25 2003-08-25
US53313203P 2003-12-30 2003-12-30
PCT/US2004/027451 WO2005020904A2 (en) 2003-08-25 2004-08-24 Oral neurotherapeutic cefazolin compositions

Publications (1)

Publication Number Publication Date
BRPI0413908A true BRPI0413908A (pt) 2006-10-24

Family

ID=34278555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413908-9A BRPI0413908A (pt) 2003-08-25 2004-08-24 formulação farmacêutica neuroterapêutica em forma de dosagem oral, composto, e, método de tratamento de um distúrbio comportamental ou um distúrbio cognitivo

Country Status (9)

Country Link
US (2) US7833998B2 (pt)
EP (1) EP1660506A4 (pt)
JP (1) JP2007503447A (pt)
KR (1) KR20070026295A (pt)
AU (1) AU2004268593B2 (pt)
BR (1) BRPI0413908A (pt)
CA (1) CA2536910A1 (pt)
MX (1) MXPA06002125A (pt)
WO (1) WO2005020904A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE635105C (de) 1936-09-10 Paul Matthiessen Verbesserung der Propulsionswirkung bei schnellfahrenden Mehrschraubenschiffen
DE635104C (de) 1934-03-11 1936-09-10 Robert Bosch Akt Ges Scheinwerfer, der in einer OEffnung der Wand oder Ummantelung eines Fahrzeuges, insbesondere Kraftfahrzeugs, eingebaut ist
US3275626A (en) * 1962-07-31 1966-09-27 Lilly Co Eli Penicillin conversion via sulfoxide
US4138555A (en) * 1971-05-14 1979-02-06 Glaxo Laboratories, Limited (6R,7R)-7-[2-aryl-2-(etherified oximino)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid 1-oxides
CA1031768A (en) * 1973-01-17 1978-05-23 Fujisawa Pharmaceutical Co. Process for preparing 3-substituted methyl-2 or 3-cephem-4-carboxylic acids
DE2716677C2 (de) * 1977-04-15 1985-10-10 Hoechst Ag, 6230 Frankfurt Cephemderivate und Verfahren zu ihrer Herstellung
US4237128A (en) * 1979-04-12 1980-12-02 E. R. Squibb & Sons, Inc. 7-[2-(2-Amino-4-thiazolyl)-2-[(1-carboxy-1,1-dialkyl)alkoxyimino]acetamido]cephem sulfoxides
US4275062A (en) * 1979-09-19 1981-06-23 E. R. Squibb & Sons, Inc. Aminothiazolyl ureido sulfoxide cephalosporins
US4349672A (en) * 1979-11-29 1982-09-14 Hoffmann-La Roche Inc. Cephalosporin derivatives
FR2476087A1 (fr) * 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
FR2485540A1 (fr) * 1980-06-30 1981-12-31 Sanofi Sa Nouveaux derives antibiotiques des cephalosporines, leur procede de preparation et les medicaments en contenant
ZA816849B (en) * 1980-10-10 1982-09-29 Hoffmann La Roche Acyl derivatives
US4458072A (en) * 1980-10-10 1984-07-03 Hoffmann-La Roche Inc. Acyl derivatives
US4547371A (en) * 1983-04-18 1985-10-15 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
US5132301A (en) * 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
US5147871A (en) * 1986-07-03 1992-09-15 Hoffmann La-Roche, Inc. Anti-bacterial cephalosporin compounds
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
US5264429A (en) * 1989-10-06 1993-11-23 Synphar Laboratories, Inc. 2-spirocyclopropyl cephalosporin sulfone derivatives
EP0494914B1 (en) * 1989-10-06 1998-12-23 Synphar Laboratories Inc. 2-spirocyclopropyl cephalosporin derivatives and processes for the preparation thereof
CA2067745A1 (en) * 1989-10-16 1991-04-17 Paulus Gerhardus Johannes Nieuwenhuis Conversion of penicillins and cephalosporins to 1-(s)-sulfoxides
US5258377A (en) * 1991-04-08 1993-11-02 Taiho Pharmaceutical Co., Ltd. 2-spirocyclopropyl 4-acylcephems
US5446037A (en) * 1991-12-05 1995-08-29 Synphar Laboratories, Inc. 2-[(substituted) methylene]cephalosporin sulfones as antiinflammatory, antidegenerative and antithrombin agents
GB9207715D0 (en) * 1992-04-08 1992-05-27 Erba Carlo Spa 2,2-disubstituted cephem sulphones
JPH0665253A (ja) * 1992-06-19 1994-03-08 Teijin Ltd 可溶性セファロスポリン誘導体
JPH0680673A (ja) * 1992-07-13 1994-03-22 Teijin Ltd 可溶性セファロスポリン化合物
US5439904A (en) * 1993-12-07 1995-08-08 Synphar Laboratories, Inc. 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents
US5760027A (en) * 1996-12-06 1998-06-02 Research Corporation Technologies, Inc. Use of 7-alkylidene cephalosporins to inhibit elastase activity
US6495539B1 (en) * 1998-02-19 2002-12-17 Washington University B-lactam-like chaperone inhibitors
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
CA2398567A1 (en) * 2000-02-11 2001-08-16 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
JP2005501806A (ja) * 2001-01-12 2005-01-20 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア フェノール性エーテルを有する、β−ラクタマーゼの基質
ATE339424T1 (de) * 2001-07-24 2006-10-15 Univ Southern Methodist 3-substituierte 7-alkylidene-3-cephem-4- carbonsäuren als beta-lactamase inhibitoren
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
AR039774A1 (es) * 2002-05-01 2005-03-02 Wyeth Corp 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas
WO2004104006A2 (en) * 2003-05-16 2004-12-02 Wyeth Holdings Corporation PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES

Also Published As

Publication number Publication date
US20110046103A1 (en) 2011-02-24
EP1660506A4 (en) 2009-02-25
MXPA06002125A (es) 2006-05-31
US7833998B2 (en) 2010-11-16
JP2007503447A (ja) 2007-02-22
AU2004268593B2 (en) 2012-02-02
KR20070026295A (ko) 2007-03-08
US20080176825A1 (en) 2008-07-24
AU2004268593A1 (en) 2005-03-10
WO2005020904A3 (en) 2005-05-06
CA2536910A1 (en) 2005-03-10
WO2005020904A2 (en) 2005-03-10
EP1660506A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
EP1478371A4 (en) METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE60328128D1 (de) Verfahren zur schmerzbehandlung durch verabreichung eines antagonistischen antikörpers gegen den nervenwachstumfaktor und eines opioid-analgetikums sowie diese enthaltende zusammensetzungen
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BRPI0414082A (pt) formas de dosagem de liberação sustentada de ziprasidona
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
MXPA05006670A (es) Administracion de capsaicinoides.
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2005072308A3 (en) Cgrp receptor antagonists
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.